EMA Pre-authorisation guidance (Human Regulatory)

July 19, 2022

EMA Pre-authorisation guidance

Table of contents

These questions and answers (Q&As) provide an overview of the European Medicines Agency's (EMA) advice on issues that are typically addressed in discussions or meetings with marketing authorisation holders in the application phase.

PDF versions of Q&As

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: Document with tracked changes

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




EMA Europe

June 20, 2022

Validation checklist for initial marketing authorisation applications - biologicals other than immunologicals (applicable to submissions under Regulation (EU) 2019/6)

JUNE 2022 EMA/278419/2022-Rev.1 This validation checklist is used by the Agency to validate initial marketing authorization applications for pharmaceuticals and applicants should use it as a means to...

Read the Full Article
EMA MAH

June 2, 2022

EMA: Procedural advice for vaccine platform technology master 5 file (vPTMF) certification (DRAFT)

This document is intended to provide advice to marketing authorisation (MA) applicants and marketing authorisation holders (MAHs) on issues associated with the submission, evaluation, certification...

Read the Full Article
pesticides Europe

July 5, 2022

Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides in food of animal origin

In 2020, the European Commission (EC) requested EMA and European Food Safety Authority (EFSA) for advice for the development of a harmonised approach on exposure assessment methodologies for residues...

Read the Full Article